MYC and cancer: Cancer metabolic reprogramming is now considered as a hallmark of cancer and is largely driven by oncogenic and tumor suppressor gene deregulations, involving notably TP53, AMPK, AKT, mTOR, HIF-1α, HIF-2α and/or MYC [12–16].